- Current report filing (8-K)
November 10 2010 - 12:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Filed Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report
(Date
of earliest event reported): November 9, 2010
Repros
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-15281
|
76-0233274
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
2408
Timberloch Place, Suite B-7
The
Woodlands, Texas 77380
(Address
of principal
executive
offices
and
zip code)
|
|
(281)
719-3400
(Registrant’s
telephone number, including area code)
|
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of Operations and Financial Condition.
The
information in this Item of this Current Report is being furnished pursuant to
Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the
information in this Item of this Current Report shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that Section. The information in this Item of this
Current Report shall not be incorporated by reference into any registration
statement pursuant to the Securities Act of 1933, as amended.
On
November 10, 2010, Repros Therapeutics Inc. (the “Company”) announced financial
results for the third quarter ended September 30, 2010. Additional
information is included in the Company’s press release dated November 10,
2010.
A copy of
the Company’s press release is attached hereto as Exhibit 99.1. The
foregoing description of the press release is qualified in its entirety by
reference to the attached exhibit.
Item
8.01 Other Events.
On
November 9, 2010, the Company issued a press release titled “Repros®
Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal® in
the Treatment of Secondary Hypogonadism.” A copy of such press
release is attached hereto as Exhibit 99.2 and is incorporated herein by
reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
.
Exhibit
|
|
Number
|
Description
|
|
|
99.1
|
Earnings
Release dated November 10, 2010
|
|
|
99.2
|
Press
Release dated November 9, 2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Repros
Therapeutics Inc.
|
|
|
|
|
|
Date: November
10, 2010
|
By:
|
/s/
Katherine A. Anderson
|
|
|
|
Katherine
A. Anderson
|
|
|
|
Chief
Accounting Officer
|
|
|
|
|
|
EXHIBIT
INDEX
Exhibit
|
|
Number
|
Description
|
|
|
99.1
|
Earnings
Release dated November 10, 2010
|
|
|
99.2
|
Press
Release dated November 9, 2010
|
Repros Therapeutics Inc. (MM) (NASDAQ:RPRXD)
Historical Stock Chart
From Apr 2024 to May 2024
Repros Therapeutics Inc. (MM) (NASDAQ:RPRXD)
Historical Stock Chart
From May 2023 to May 2024